Age-related thymic involution describes the progressive shrinkage of the thymus gland and the decline in its output of naive T cells. By the seventh decade of life, the thymic epithelial space is largely replaced by adipose tissue, and circulating naive T cell numbers fall sharply. This process is considered a central driver of immunosenescence, the age-associated deterioration of immune competence. Researchers have long sought interventions that might restore thymic function or at least slow its decline. Among the compounds examined in this context are NAD+ precursors and the copper peptide GHK-Cu, alongside a group of short peptides known as bioregulators, including Cortagen, Pinealon, Vesugen, and Epitalon.
The question of whether any of these agents can meaningfully enhance thymopoiesis in adults over 60 remains open. Soviet-era research on peptide bioregulators often reported improvements in immune parameters in elderly cohorts, but many of those studies were small, lacked rigorous controls, or were published in journals with limited international circulation. More recent work on NAD+ and GHK-Cu has focused on cellular energetics, epigenetic regulation, and tissue remodeling, with only indirect connections to thymic biology. This article reviews the available evidence for NAD+, GHK-Cu, and Cortagen in the context of thymic involution and immune rejuvenation, with attention to the limitations of the underlying data.
NAD+ and Thymic Involution: Energetic Constraints on Thymopoiesis
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme central to cellular redox reactions and a substrate for sirtuins, poly(ADP-ribose) polymerases, and other enzymes involved in DNA repair and metabolic regulation. Levels of NAD+ decline with age in many tissues, including the thymus, and this decline has been proposed to contribute to the functional deterioration of thymic epithelial cells. A 2020 study by Minhas and colleagues in Nature Metabolism reported that restoring NAD+ levels in aged mice improved mitochondrial function in multiple organs and partially reversed some age-related immune phenotypes. However, that study did not specifically measure thymic output or naive T cell production.
In a 2022 review published in Trends in Immunology, Zhang and colleagues discussed the role of NAD+ metabolism in T cell development and thymic involution. They noted that thymic epithelial cells are highly dependent on oxidative phosphorylation and that NAD+ depletion may impair their ability to support thymocyte maturation. The authors suggested that NAD+ precursors such as nicotinamide riboside or nicotinamide mononucleotide might theoretically improve thymic function, but they emphasized that direct evidence from human trials is lacking. Most human studies of NAD+ precursors have measured safety, blood NAD+ levels, or general markers of aging, not thymic output.
There is also the matter of delivery. The thymus is a relatively inaccessible organ, and systemic administration of NAD+ precursors may not achieve sufficient concentrations in the thymic microenvironment. Some researchers have proposed that local or targeted delivery methods might be necessary to influence thymopoiesis directly. Others have argued that the primary benefit of NAD+ restoration for immune aging may occur in peripheral T cells rather than in the thymus itself. Except, and this matters, peripheral T cell function is also compromised by the loss of naive cells, so a purely peripheral effect would not address the root cause of immunosenescence.
For readers interested in how NAD+ intersects with other anti-aging strategies, a related discussion on NAD+ and Epitalon for epigenetic anti-aging effects may provide useful context. The thymic involution problem is distinct from telomere attrition, but both are hallmarks of immune aging.
GHK-Cu: Copper Peptide and Tissue Remodeling in the Thymus
GHK-Cu is a naturally occurring copper-binding tripeptide that was first isolated from human plasma in the 1970s. It has been studied for its effects on wound healing, collagen synthesis, and modulation of inflammatory cytokines. In the context of aging, GHK-Cu has been shown to influence gene expression patterns in a manner that partially reverses age-related changes in fibroblasts and other cell types. A 2019 trial by Pickart and colleagues, published in the Journal of Biomaterials and Nanobiotechnology, reported that GHK-Cu upregulated genes associated with tissue repair and downregulated genes linked to chronic inflammation in cultured human cells.
Whether GHK-Cu can directly affect thymic epithelial cells or thymocyte development is less clear. The thymus undergoes a process of fibrosis and adipogenesis during involution, and some researchers have speculated that GHK-Cu's anti-fibrotic and pro-angiogenic properties might slow this process. However, no published study has specifically examined GHK-Cu in a model of thymic involution. The peptide's effects on skin and connective tissue are well documented, but extrapolating those findings to the thymic stroma is not straightforward. The thymic microenvironment is unique in its cellular composition and signaling requirements.
One possible mechanism by which GHK-Cu could influence thymopoiesis is through its modulation of systemic inflammation. Chronic low-grade inflammation, often termed inflammaging, is thought to accelerate thymic involution by promoting thymic epithelial cell apoptosis and adipocyte differentiation. GHK-Cu has been reported to reduce the expression of pro-inflammatory cytokines such as tumor necrosis factor-alpha and interleukin-6 in several experimental systems. If these effects occur in the thymic microenvironment, they might indirectly support thymic function. But this remains speculative, and the available evidence is indirect at best.
Another consideration is the interaction between GHK-Cu and other peptides. Some researchers have proposed that combining GHK-Cu with bioregulators like Cortagen or Epitalon might produce synergistic effects on tissue repair and immune function. A previous article on this site examined GHK-Cu and Cortagen for epigenetic skin aging, but the thymic application is a different question entirely.
Cortagen and Thymopoiesis: Soviet-Era Bioregulator Research
Cortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Pro) derived from the cortex of the brain, according to the original Soviet literature. It belongs to a class of compounds known as cytomedins or bioregulators, which were developed at the Kirov Military Medical Academy in Leningrad during the 1980s. The theoretical framework behind these peptides posited that short peptides derived from specific tissues could restore the function of those tissues when administered to aging organisms. Cortagen was originally studied for its effects on the central nervous system, but some Soviet researchers also reported effects on immune parameters.
A 1987 study by Morozov and Khavinson, published in the Bulletin of Experimental Biology and Medicine, reported that Cortagen administration to aged rats increased thymic weight and the number of thymocytes in the cortex. The authors interpreted this as evidence of enhanced thymopoiesis, though the study lacked modern immunohistochemical or flow cytometric analyses. Subsequent work by the same group suggested that Cortagen and related peptides could modulate the expression of genes involved in cell proliferation and differentiation. However, these findings have not been independently replicated in Western laboratories, and the original data are difficult to access.
The relevance of Cortagen to thymic involution in humans over 60 is uncertain. The Soviet-era studies used animal models and relatively short treatment periods. Human trials of Cortagen for neurological conditions have been conducted in Russia, but none have specifically measured thymic output or naive T cell counts. In a 2015 review published in Advances in Gerontology, Khavinson and colleagues summarized the evidence for peptide bioregulators in aging, including Cortagen, but acknowledged that the mechanisms of action remain poorly understood. The review noted that Cortagen may influence gene expression through interactions with DNA or transcription factors, but the specific targets in thymic epithelial cells have not been identified.
There is also the question of whether Cortagen's effects, if any, are specific to the thymus or reflect a more general anti-stress or neuroendocrine action. The thymus is highly sensitive to glucocorticoids and catecholamines, and peptides that modulate the hypothalamic-pituitary-adrenal axis could indirectly affect thymic function. Cortagen was originally developed as a neuroprotective agent, and its effects on the thymus may be secondary to changes in stress hormone signaling. This possibility has not been systematically investigated.
For those interested in how Cortagen might interact with other peptides, a related discussion on NAD+ restoration after viral illness with GHK-Cu and Epitalon touches on overlapping themes of immune repair and peptide synergy.
Comparative Evidence: NAD+, GHK-Cu, and Cortagen for Thymic Rejuvenation
Direct comparative studies of NAD+, GHK-Cu, and Cortagen for thymic involution do not exist. The three compounds act through different mechanisms and have been studied in different experimental contexts. NAD+ precursors target cellular energetics and sirtuin activity. GHK-Cu targets tissue remodeling and inflammatory signaling. Cortagen, if it works as described in the Soviet literature, targets gene expression in a tissue-specific manner. Whether these mechanisms converge on thymopoiesis is unknown.
One way to approach the question is to consider what is known about the biology of thymic involution. The process is driven by a combination of intrinsic changes in thymic epithelial cells, alterations in the thymic microenvironment, and systemic factors such as sex steroids and growth hormone. Interventions that address only one of these factors are unlikely to produce robust rejuvenation. NAD+ restoration might improve thymic epithelial cell metabolism, but it would not address the loss of thymic epithelial cells themselves. GHK-Cu might reduce fibrosis, but it would not restore the thymic epithelial cell population. Cortagen, if it truly enhances thymocyte proliferation, might increase thymic output, but the supporting evidence is weak.
A 2023 review by Palmer and colleagues in Aging Cell examined the potential of various interventions for thymic rejuvenation, including growth hormone, sex steroid ablation, and interleukin-7. The authors did not discuss NAD+, GHK-Cu, or Cortagen, which reflects the limited attention these compounds have received in mainstream thymus research. This absence is notable, given the popularity of these agents in the broader anti-aging community. It suggests that the evidence base for their thymic effects is considered insufficient by most immunologists.
That said, the lack of evidence is not evidence of absence. The Soviet literature on peptide bioregulators is largely inaccessible to Western researchers, and the quality of that literature is difficult to assess. Some of the reported effects may be real but poorly documented. Others may be artifacts of small sample sizes or inadequate controls. Until independent replication studies are conducted, the question of Cortagen's thymic effects will remain unresolved.
For a broader perspective on how these compounds fit into anti-aging research, readers may find value in a previous article on NAD+ and Pinealon for mitochondrial anti-aging effects. The mitochondrial and thymic aging processes share some common features, including the accumulation of senescent cells and metabolic dysfunction.
Clinical Considerations for Adults Over 60
Adults over 60 face a unique set of challenges when considering interventions for thymic involution. The thymus has already undergone substantial involution by this age, and the potential for regeneration is limited. Some studies have shown that thymic function can be partially restored in older adults through growth hormone administration or sex steroid ablation, but these interventions carry significant risks and are not widely used. The question is whether milder interventions like NAD+ precursors, GHK-Cu, or Cortagen could achieve even a fraction of that effect with fewer side effects.
Safety data for NAD+ precursors in older adults are relatively robust. Nicotinamide riboside and nicotinamide mononucleotide have been tested in multiple human trials, with generally mild side effects such as nausea, fatigue, and headache. However, these trials have not measured thymic output, and the long-term effects of NAD+ restoration on immune function are unknown. GHK-Cu has been used topically for skin conditions and is generally well tolerated, but systemic administration in older adults has not been extensively studied. Cortagen has been used in Russia for neurological conditions, but its safety profile in Western populations is not established.
Another consideration is the potential for interactions between these compounds and medications commonly used by older adults. NAD+ precursors may affect glucose metabolism and could interact with diabetes medications. GHK-Cu may affect copper homeostasis and could interact with chelating agents or other metal-binding drugs. Cortagen's interactions are largely unknown due to the limited clinical data. Anyone considering these compounds should consult a physician familiar with their pharmacology, though such physicians are rare outside of specialized anti-aging clinics.
The regulatory status of these compounds also varies. NAD+ precursors are widely available as dietary supplements in many countries. GHK-Cu is available as a cosmetic ingredient and, in some cases, as a research
Specific outcomes referenced from studies represent observed effects in defined populations under defined conditions.